Luyendyk James P, Mattes William B, Burgoon Lyle D, Zacharewski Timothy R, Maddox Jane F, Cosma Gregory N, Ganey Patricia E, Roth Robert A
Department of Pharmacology and Toxicology, National Food Safety and Toxicology Center, Center for Integrative Toxicology, Michigan State University, East Lansing, Michigan 48824, USA.
Toxicol Sci. 2004 Jul;80(1):203-13. doi: 10.1093/toxsci/kfh146. Epub 2004 Apr 14.
Studies in rats have demonstrated that modest underlying inflammation can precipitate idiosyncratic-like liver injury from the histamine 2-receptor antagonist, ranitidine (RAN). Coadministration to rats of nonhepatotoxic doses of RAN and the inflammagen, bacterial lipopolysaccharide (LPS), results in hepatocellular injury. We tested the hypothesis that hepatic gene expression changes could be distinguished among vehicle-, LPS-, RAN- and LPS/RAN-treated rats before the onset of significant liver injury in the LPS/RAN-treated rats (i.e., 3 h post-treatment). Rats were treated with LPS (44 x 10(6) EU/kg, i.v.) or its vehicle, then two hours later with RAN (30 mg/kg, i.v.) or its vehicle. They were killed 3 h after RAN treatment, and liver samples were taken for evaluation of liver injury and RNA isolation. Hepatic parenchymal cell injury, as estimated by increases in serum alanine aminotransferase (ALT) activity, was not significant at this time. Hierarchal clustering of gene expression data from Affymetrix U34A rat genome array grouped animals according to treatment. Relative to treatment with vehicle alone, treatment with RAN and/or LPS altered hepatic expression of numerous genes, including ones encoding products involved in inflammation, hypoxia, and cell death. Some were enhanced synergistically by LPS/RAN cotreatment. Real-time PCR confirmed robust changes in expression of B-cell translocation gene 2, early growth response-1, and plasminogen-activator inhibitor-1 (PAI-1) in cotreated rats. The increase in PAI-1 mRNA was reflected in an increase in serum PAI-1 protein concentration in LPS/RAN-treated rats. Consistent with the antifibrinolytic activity of PAI-1, significant fibrin deposition occurred only in livers of LPS/RAN-treated rats. The results suggest the possibility that expression of PAI-1 promotes fibrin deposition in liver sinusoids of LPS/RAN-treated rats and are consistent with the development of local ischemia and consequent tissue hypoxia.
对大鼠的研究表明,适度的潜在炎症可促使组胺2受体拮抗剂雷尼替丁(RAN)引发特异质性肝损伤。给大鼠联合使用非肝毒性剂量的RAN和炎症原细菌脂多糖(LPS)会导致肝细胞损伤。我们检验了这样一个假设:在LPS/RAN处理组大鼠出现明显肝损伤之前(即处理后3小时),可以区分出接受赋形剂、LPS、RAN以及LPS/RAN处理的大鼠之间肝脏基因表达的变化。给大鼠静脉注射LPS(44×10⁶ EU/kg)或其赋形剂,两小时后再静脉注射RAN(30 mg/kg)或其赋形剂。RAN处理3小时后将大鼠处死,取肝脏样本评估肝损伤并进行RNA分离。此时,通过血清丙氨酸转氨酶(ALT)活性升高估算的肝实质细胞损伤并不显著。来自Affymetrix U34A大鼠基因组阵列的基因表达数据的层次聚类根据处理方式对动物进行了分组。相对于单独使用赋形剂处理,RAN和/或LPS处理改变了众多基因的肝脏表达,包括那些编码参与炎症、缺氧和细胞死亡相关产物的基因。有些基因在LPS/RAN联合处理时协同增强。实时PCR证实,联合处理的大鼠中B细胞易位基因2、早期生长反应-1和纤溶酶原激活物抑制剂-1(PAI-1)的表达发生了显著变化。LPS/RAN处理的大鼠中PAI-1 mRNA的增加反映在血清PAI-1蛋白浓度的升高。与PAI-1的抗纤维蛋白溶解活性一致,仅在LPS/RAN处理的大鼠肝脏中出现了显著的纤维蛋白沉积。结果表明,PAI-1的表达可能促进了LPS/RAN处理的大鼠肝窦中的纤维蛋白沉积,这与局部缺血及随之而来的组织缺氧的发展是一致的。